Claims for Patent: 10,266,822

Summary for Patent: 10,266,822

Title:	Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Abstract:	The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).
Inventor(s):	Ravindra N. Singh, Natalia N. Singh, Nirmal K. Singh, Elliot J. Androphy
Assignee:	University of Massachusetts Amherst
Application Number:	US15/269,259
Patent Claims:	1. A method of increasing the level of exon 7-containing SMN2 mRNA in a cell or cell extract comprising contacting the cell or cell extract with an oligonucleotide, which oligonucleotide comprises a sequence sufficiently complementary to intron 7 of the SMN2 gene over the entire length of the oligonucleotide and sufficiently complementary to the sequence CCAGCAUUAUGAAAG (SEQ ID NO:3), such that the level of exon 7-containing SMN2 mRNA in the cell is increased. 2. The method of claim 1, wherein the oligonucleotide is between about 5 and about 50 nucleotides in length. 3. The method of claim 1, wherein the oligonucleotide is modified by substitution of at least one nucleotide with a modified nucleotide such that in vivo stability is enhanced as compared to an unmodified oligonucleotide. 4. The method of claim 3, wherein the modified nucleotide is selected from the group consisting of: a sugar-modified nucleotide; a nucleobase-modified nucleotide; a 2′-deoxy ribonucleotide; a 2′-O-methyl ribonucleotide; a 2′-fluoro modified ribonucleotide; a 2′-amino modified ribonucleotide; a 2′-thio modified ribonucleotide; a 5-bromo-uridine; a 5-iodo-uridine; a 5-methyl-cytidine; a ribo-thymidine; a 2-aminopurine; a 5-fluoro-cytidine; a 5-fluoro-uridine; a 2,6-diaminopurine; a 4-thio-uridine; a 5-amino-allyl-uridine; a backbone-modified nucleotide; and a locked nucleic acid (LNA). 5. The method of claim 4, wherein the 2′-deoxy ribonucleotide is 2′-deoxy adenosine or 2′-deoxy guanosine. 6. The method of claim 4, wherein the 2′-fluoro modified nucleotide is 2′-fluoro-cytidine, 2′-fluoro-uridine, 2′-fluoro-adenosine, or 2′-fluoro-guanosine, or wherein the 2′-amino modified ribonucleotide is 2′-amino-cytidine, 2′-amino-uridine, 2′-amino-adenosine, 2′-amino-guanosine or 2′-amino-butyryl-pyrene-uridine. 7. The method of claim 4, wherein the backbone-modified nucleotide contains a phosphorothioate group. 8. The method of claim 1, wherein the cell or cell extract is a spinal muscular atrophy (SMA) patient-derived neuronal cell, muscle cell or fibroblast, or extract thereof. 9. The method of claim 1, wherein the cell or cell extract is selected from the group consisting of an embryonic stem cell, an embryonic stem cell extract, a neuronal stem cell and a neuronal stem cell extract. 10. A method of increasing the level of exon 7-containing SMN2 mRNA in an organism, comprising administering to the organism an oligonucleotide, which oligonucleotide comprises a sequence sufficiently complementary to intron 7 of the SMN2gene over the entire length of the oligonucleotide and sufficiently complementary to the sequence CCAGCAUUAUGAAAG (SEQ ID NO:3), such that the level of exon 7-containing SMN2 mRNA in the organism is increased. 11. The method of claim 10, wherein the organism is a mammal. 12. The method of claim 10, wherein the organism is a human. 13. The method of claim 10, wherein the human has spinal muscular atrophy (SMA). 14. A method of treating spinal muscular atrophy (SMA) in a patient, comprising administering to the patient an oligonucleotide, which oligonucleotide comprises a sequence sufficiently complementary to intron 7 of the SMN2 gene over the entire length of the oligonucleotide and sufficiently complementary to the sequence CCAGCAUUAUGAAAG (SEQ ID NO:3), in a dose effective to increase the level of exon 7-containing SMN2 mRNA in cells of the patient, such that SMA in the patient is treated. 15. A method of treating a subject that would benefit from increased levels of exon 7-containing SMN2mRNA in neuronal cells, comprising administering to the patient an oligonucleotide, which oligonucleotide comprises a sequence sufficiently complementary to intron 7 of the SMN2 gene over the entire length of the oligonucleotide and sufficiently complementary to the sequence CCAGCAUUAUGAAAG (SEQ ID NO:3), in a dose effective to increase the level of exon 7-containing SMN2 mRNA in cells of the subject. 16. The method of claim 15, wherein the subject is suffering from amyotrophic lateral sclerosis (ALS). 17. A method of increasing the level of exon 7-containing SMN2 mRNA in a cell comprising contacting the cell with an oligonucleotide, which oligonucleotide comprises a sequence that is sufficiently complementary to a sequence selected from SEQ ID NO: 3, and SEQ ID NO: 40-66; such that the level of exon 7-containing SMN2mRNA in the cell is increased. 18. A method of increasing the level of exon 7-containing SMN2 mRNA in a cell comprising contacting the cell with an oligonucleotide, which oligonucleotide comprises a sequence sufficiently complementary to intron 7 of the SMN2 gene over the entire length of the oligonucleotide and complementary to nucleotide 1 and 6 of the sequence CCAGCAUUAUGAAAG (SEQ ID NO:3), such that the level of exon 7-containing SMN2 mRNA in the cell is increased. 19. The method of claim 1, wherein the oligonucleotide is between about 8 and about 19 nucleotides in length or between about 8 and about 14 nucleotides in length.